Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide

BACKGROUND: While lenalidomide (LEN) shows high efficacy in myelodysplastic syndromes (MDS) with del[5q], responses can be also seen in patients presenting without del[5q]. We hypothesized that improved detection of chromosomal abnormalities with new karyotyping tools may better predict response to...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugimoto, Yuka, Sekeres, Mikkael A, Makishima, Hideki, Traina, Fabiola, Visconte, Valeria, Jankowska, Anna, Jerez, Andres, Szpurka, Hadrian, O'Keefe, Christine L, Guinta, Kathryn, Afable, Manuel, Tiu, Ramon, McGraw, Kathy L, List, Alan F, Maciejewski, Jaroslaw
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323440/
https://www.ncbi.nlm.nih.gov/pubmed/22390313
http://dx.doi.org/10.1186/1756-8722-5-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323440/
https://www.ncbi.nlm.nih.gov/pubmed/22390313
http://dx.doi.org/10.1186/1756-8722-5-4

Ejemplares similares